2026-06-14T03:52:36Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/174472025-03-19T14:02:38Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19609col_20.500.12105_16978

00925njm 22002777a 4500 dc Fernandez-Rodriguez, Amanda author Berenguer, Juan author Jimenez-Sousa, Maria Angeles author Guzman-Fulgencio, Maria author Micheloud, Dariela author Miralles, Pilar author López, Juan Carlos author Bellón, José María author Aldámiz-Echevarria, Teresa author Garcia-Broncano, Pilar author Carrero, Ana author Alvarez, Emilio author Resino, Salvador author 2013-12-15 Objective: To assess the ability of the cirrhosis risk score (CRS) to predict liver fibrosis progression in HIV/hepatitis C virus (HCV)-coinfected patients. Design: Retrospective follow-up study. Methods: Based on a minimum follow-up time of 10 years with HCV infection, 190 HIV/HCV-coinfected patients were classified according to their METAVIR score: (1) 25 nonprogressor patients who did not develop fibrosis (F0) and (2) 165 progressor patients who developed fibrosis (F ≥ 1). Seven polymorphisms of CRS signature and IL28B genotype were performed using the GoldenGate assay. The CRS signature was calculated by naive Bayes formula as previously described. Results: Nonprogressors had CRS values significantly lower than progressors (0.61 versus 0.67; P = 0.043). Among the progressors, we observed similar CRS values through all the fibrosis stages (F1/F2/F3/F4). The percentage of patients with CRS > 0.70 (high risk of developing fibrosis) was higher in progressors than in nonprogressors; but the percentages with values between 0.50 and 0.70 (intermediate risk) and <0.50 (low risk) were quite similar for each of the fibrosis stages (P = 0.047). The area under the receiver-operating characteristic curve of CRS for discriminating nonprogressor versus progressor was 0.625 (P = 0.043). When clinical variables were considered (age at HCV infection, intravenous drug use, gender, IL28B, and HCV genotype), the area under the receiver-operating characteristic curve of CRS improved up to 0.739 (P < 0.001). Conclusions: CRS itself seems not to be a good marker for identifying HIV/HCV-coinfected patients who are at high risk of developing liver fibrosis. However, CRS score coupled with clinical factors might help to distinguish between nonprogressors and progressors patients. J Acquir Immune Defic Syndr. 2013 Dec 15;64(5):434-42. 10.1097/QAI.0b013e3182a06eb6 1944-7884 Journal of acquired immune deficiency syndromes (1999) 23797694 http://hdl.handle.net/20.500.12105/17447 AIDS Chronic hepatitis C Genetic polymorphisms Liver fibrosis Predictive genetic markers Prediction of hepatic fibrosis in patients coinfected with HIV and hepatitis C virus based on genetic markers